Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 4.6% – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price was down 4.6% during mid-day trading on Thursday . The stock traded as low as $21.90 and last traded at $21.63. Approximately 10,387 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 310,105 shares. The stock had previously closed at $22.66.

Analyst Upgrades and Downgrades

DNTH has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. TD Cowen initiated coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating for the company. Finally, Oppenheimer boosted their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, November 11th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Dianthus Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Trading Down 4.5 %

The company has a market capitalization of $640.40 million, a P/E ratio of -8.62 and a beta of 1.74. The company’s 50 day moving average is $23.27 and its 200-day moving average is $26.31.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The business had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Institutional investors have recently bought and sold shares of the company. R Squared Ltd bought a new stake in shares of Dianthus Therapeutics in the 4th quarter worth $26,000. KBC Group NV bought a new position in Dianthus Therapeutics during the 4th quarter valued at about $35,000. SG Americas Securities LLC boosted its holdings in shares of Dianthus Therapeutics by 9.2% during the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock valued at $210,000 after acquiring an additional 814 shares during the last quarter. Barclays PLC grew its stake in shares of Dianthus Therapeutics by 390.5% in the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock worth $1,141,000 after acquiring an additional 33,185 shares during the period. Finally, Jane Street Group LLC purchased a new stake in Dianthus Therapeutics in the third quarter worth approximately $556,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.